In the Rett disease model of MeCP2-deficient mice, a 4 week course of fingolimod treatment at a rather low dose (0.5 mg/kg every 4d) lead to increased levels of BDNF in affected brain structures and even to an amelioration of motor impairment and survival. This evidence concerns the gene MECP2 and Rett syndrome.